Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 Next >
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
Tickers CYBN DMTTF TSX-V:DMT
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Closing of Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in PSYCH Symposium London 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Provides Corporate Update
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Jefferies Healthcare Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 26th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.